The first procurement decision is to correct the specification: the relevant depot presentation is triptorelin 3.75 mg, not 375 mg. By the end, you will know how to verify the formulation, clinical use, UK supply route, documents, delivery controls and total cost before placing an oncology order.
Key takeaways
- Reject quotations stating 375 mg; request triptorelin 3.75 mg prolonged-release injection.
- Confirm the depot administration schedule and prescriber-approved alternative before ordering.
- Request UK licensing and import documents for a lawful supply route into England.
- Check seals, batch details, expiry, storage records and the complete injection kit.
Why “375 mg” must be corrected to triptorelin 3.75 mg
1. Correct the strength before requesting a quotation: the catalogue presentation is triptorelin 3.75 mg prolonged-release injection. “375 mg” is a material specification error, not an alternative way to write the dose; it represents 100 times the stated strength. Reject documents carrying 375 mg and request reissue.
2. Require every tender, quotation, purchase order, invoice, import document and pharmacy record to state triptorelin 3.75 mg, depot or prolonged-release formulation, injection dosage form and complete presentation, including supplied solvent and administration components.
A search phrase such as “triptorelin acetate 3 point 75 mg injection supplier in england” does not establish that the offered pack is suitable or authorised.
3. Triptorelin is a gonadotrophin-releasing hormone agonist. Initial stimulation of pituitary receptors is followed by receptor down-regulation, suppressing luteinising hormone, follicle-stimulating hormone and sex hormones. This supports oncology use, especially androgen-deprivation therapy for prostate cancer, but confirm the licensed indication for the exact product and pack in the MHRA medicine database.
4. Distinguish the active ingredient, triptorelin, from Decapeptyl, a brand name, and Ferring Pharmaceuticals, a manufacturer. Those names alone do not prove that stock is branded, licensed or sourced through an authorised chain. Confirm the exact product, indication and legal supply route before ordering.
How the 3.75 mg depot is administered and compared with alternatives
The 3.75 mg depot is usually administered every four weeks, or 28 days, according to the prescriber’s order and the exact product information. Do not assume interchangeability with another triptorelin presentation, even when the active ingredient matches.
This is not an immediate-release injection. A trained healthcare professional must reconstitute the powder with its matched supplied solvent, using the specified transfer or reconstitution device, needle, route and administration method. The pharmacy specification must state:
- Route and administration method
- Complete components supplied
- Required reconstitution time
- Acceptable visual appearance
- In-use period after reconstitution
- Sharps and medicine-disposal process
A buyer seeking a triptorelin injection supplier UK must compare the complete presentation, not a powder vial alone.
| Option | Interval and administration | Formulation and monitoring |
|---|---|---|
| 3.75 mg triptorelin | Four-week depot; reconstituted injection | GnRH agonist; monitor suppression and initial testosterone flare |
| Longer-acting triptorelin | Usually 12-week depot; reconstituted injection | Same agonist class; fewer administrations but longer scheduling and follow-up consequences |
| Goserelin 10.8 mg | Usually 12-week subcutaneous implant | GnRH agonist implant; site checks and flare monitoring |
| Leuprorelin depot | One-, three- or six-month depot; injection | GnRH agonist depot; presentation-specific preparation and monitoring |
| Degarelix | Monthly subcutaneous injection | GnRH antagonist; no equivalent initial testosterone flare |
Substitution requires clinical and formulary authorisation, not merely an active-ingredient match or the lowest unit price.
What clinical and pharmacy checks support safe oncology use
At initiation, triptorelin can cause a temporary testosterone rise and tumour flare in prostate cancer. The prescriber must decide whether a short course of anti-androgen cover is needed for patients at risk of complications; procurement plans must allow for that decision and the associated monitoring.
- Testosterone response and disease symptoms, including worsening pain or urinary symptoms.
- Injection-site reactions, hot flushes, mood changes and sexual adverse effects.
- Bone mineral density, fracture risk, metabolic changes and cardiovascular risk.
- QT-interval concerns and other adverse effects requiring pharmacovigilance review.
- Forecast patient numbers against four-week treatment cycles and planned appointments.
- Confirm prescription or formulary approval, the authorised indication and patient eligibility.
- Rotate stock by expiry and quarantine stock that cannot support the scheduled cycle.
- Record batch number and expiry at administration, then reconcile administration records against dispensed stock and appointments.
Patients must not buy this injection or self-administer it. Supply requires a prescription, and administration requires qualified healthcare supervision.
Which UK legal and import documents establish a lawful route into England
A lawful England route starts with the product record, not the supplier’s postcode. Before payment, ask for the UK marketing-authorisation number, authorisation holder, exact presentation, triptorelin 3.75 mg strength and pack size, then match each detail against the MHRA medicine database.
- If it is not UK-authorised, require the documented legal basis for supplying an unlicensed medicine, parallel import or other applicable route. Identify the licensed manufacturer, importer and wholesale dealer.
- Request the importer’s licence or wholesale-dealer authorisation, named Responsible Person where applicable, batch UK-release status, current GMP certificate or inspection evidence, certificate of analysis, batch-release documentation and certificate of conformity where supplied.
- Obtain the invoice and packing list before dispatch, and ensure they identify the exact product, quantity, batch and destination.
| Destination | Route to verify | Procurement warning |
|---|---|---|
| England or Great Britain | UK marketing authorisation or documented alternative legal route | “UK supply” is too vague |
| Northern Ireland | EU medicines rules under the Windsor Framework | Do not reuse a Great Britain route |
An English supplier address does not prove local stock, UK compliance or permission to place imported medicine on the market. Require the quotation to name England or another Great Britain destination. A search for “buy triptorelin injection in England” proves nothing about authorisation.
What to inspect on receipt, during storage and when stock looks suspicious
1. On receipt, inspect the carton and every component against the purchase order. Confirm English-language labelling where required, product name, triptorelin 3.75 mg strength, dosage form, batch number, expiry date, storage statement, manufacturer or authorisation-holder details, tamper evidence and the patient information leaflet.
Check for the complete presentation: powder, matched solvent, syringe, needle and reconstitution device where specified. A “1 ml vial” description alone does not prove a complete 3.75 mg dose.
2. Obtain the manufacturer’s approved storage range, excursion limits, shipping validation and temperature records for this exact presentation. Do not infer conditions from another medicine listing or automatically require cold-chain transport; use the product’s label and stability evidence.
3. Quarantine stock with a mismatched strength, damaged carton, broken seal, missing batch or expiry data, unexplained relabelling, or inconsistent serialisation or aggregation data. Photograph the stock, retain delivery documents, notify the supplier and follow the pharmacy’s deviation and recall process.
Treat unusually low prices, missing traceability and an unclear distribution chain as diversion or counterfeit risks. Record the inspection and release decision in the receipt log.
How to compare a supplier’s complete-dose offer before ordering
Request a triptorelin 3 point 75 mg injection wholesale quotation for a complete four-week depot dose, not a vial price alone. Ask for:
- Product identifier, brand or equivalent status, manufacturer, authorisation holder, complete presentation, number of complete doses, batch and expiry, and remaining shelf life on arrival.
- MOQ, including the stated 10-vial minimum, dispatch lead time, delivery address, insurance, VAT, customs and other import charges.
- Confirmation that each pack includes its matched solvent, syringe, needle and transfer or reconstitution device.
- Storage and transport evidence, temperature-excursion liability, certificate of analysis, batch-release records and traceability.
- Complaint handling, rejected-batch replacement, recall notification, shortage communication and returns policy.
Compare the landed cost per usable dose against patient numbers, four-week schedules, expiry and unused-dose risk:
| Option | Cost basis | Risk to test |
|---|---|---|
| Ex-factory vial | Supplier price only | Excludes freight, VAT, customs and unusable stock |
| Complete dose | Delivered pack with solvent and devices | Confirms the dose can be administered |
| Usable dose | Delivered cost after expiry and rejects | Reveals the real procurement cost |
NIBA HEALTHCARE can be approached for a tender or wholesale enquiry, but test its status as a triptorelin acetate injection exporter against MHRA, licensing, product and supply-chain evidence before ordering.
Related product
 | Anti Cancer Injection Triptorelin Acetate 3.75 Mg Injection Minimum order quantity 10 Vial Packaging Size 1 ml Packaging Type Vial Brand Decapeptyl Manufacturer Ferring Pharmaceuticals Country of Origin Made... View product → |
Frequently asked questions
Is triptorelin 375 mg injection the correct strength?
No. The oncology depot presentation is triptorelin 3.75 mg prolonged-release injection. A 375 mg statement is 100 times the stated strength, so reject the document and request a corrected quotation.
How is triptorelin 3.75 mg depot injection administered?
A trained healthcare professional reconstitutes and administers the prolonged-release depot according to the authorised product information and the prescriber’s treatment schedule. Confirm the route, interval and complete reconstitution kit before supply.
Which documents support lawful triptorelin import into England?
Ask the supplier to provide the product’s UK authorisation or applicable regulatory basis, manufacturer and batch documents, a commercial invoice, packing list, transport records and any required UK import or wholesale-dealer licence evidence. Your responsible pharmacist or regulatory adviser must confirm which documents apply to the route.
What should you inspect when triptorelin stock arrives?
Check the product name and 3.75 mg strength, batch number, expiry date, tamper seal, packaging, diluent and reconstitution components. Compare the shipment with its temperature records and quarantine stock with missing, damaged or suspicious details.
